PANDAS and PANS are debilitating conditions characterised by distressing symptoms, ranging from rage to signs of obsessive compulsive disorder.
Read More
Traditional cannabis in the form of oil has had an absorption problem, making it less effective. But what if you blended it with starch, which boasts greater absorption without messing with the compound? Cannabis-focused drug development company Bod Science (ASX: BOD) undertook a study on the same, delivering some positive results. So positive, in fact,
Read More
Once again, medical cannabis producer Vitura Health (ASX: VIT) has become the only ASX-listed company operating in the medicinal cannabis space to both generate a profit and declare a dividend since its ASX initiation in 2019. The Company will pay a dividend to shareholders in respect of FY23. The Dividend, which will be paid at
Read More
After changing its name and identity, cannabis and psychedelics provider Melodiol (ASX: ME1) has decided to sell off two of its most prominent business units, Sierra Sage Herbs and Halucenex Life Sciences to US-based Panacea Life Sciences for $7.56 million in cash and shares. Panacea Life Sciences focuses on the production, research, and distribution of
Read More
As of 2022, Australia is witnessing nearly 400,000 individuals grappling with dementia. Dementia is the second leading cause of death in Australia, and if the trend continues, it might just claim the top spot as the leading cause. But that’s not all – two out of three people with dementia are not hiding away in
Read More
Cannabis is the most widely-used illicit drug worldwide; about 2.5% of the world, i.e. approximately 150 million people, consume cannabis, and Australia is among the top countries leading the trend. While it sounds the alarm on the concerning drug abuse problem, it also signals a profitable market for companies in the field. Cannabis-based medicine and
Read More